EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

被引：3
|
作者：
Le, Xiuning [1 ]
Nadler, Eric [2 ]
Costa, Daniel B. [3 ]
Heymach, John Victor [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
来源：
TARGETED ONCOLOGY | 2023年 / 18卷 / 06期
关键词：
AFATINIB; OSIMERTINIB; NSCLC;
D O I：
10.1007/s11523-023-00994-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[media not available: see fulltext]
引用
收藏
页码：807 / 817
页数：11
相关论文
共 50 条
  • [21] Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations
    Igawa, Satoshi
    Ryuge, Shiichiro
    Ichinoe, Masaaki
    Nakashima, Hiroyasu
    Otani, Sakiko
    Nakahara, Yoshiro
    Fukui, Tomoya
    Sasaki, Jiichiro
    Kubota, Masaru
    Katagiri, Masato
    Murakumo, Yoshiki
    Satoh, Yukitoshi
    Sato, Yuichi
    Masuda, Noriyuki
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 7 - 13
  • [22] Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    BIOLOGY-BASEL, 2020, 9 (10): : 1 - 10
  • [23] Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    Chantharasamee, J.
    Poungvarin, N.
    Danchaivijitr, P.
    Techawatanawanna, S.
    BMC CANCER, 2019, 19 (1)
  • [24] Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    J. Chantharasamee
    N. Poungvarin
    P. Danchaivijitr
    S. Techawatanawanna
    BMC Cancer, 19
  • [25] Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations
    Sugiyama, Eri
    Umemura, Shigeki
    Nomura, Shogo
    Kirita, Keisuke
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Niho, Seiji
    Ohmatsu, Hironobu
    Tsuboi, Masahiro
    Ohe, Yuichiro
    Goto, Koichi
    LUNG CANCER, 2015, 90 (02) : 307 - 313
  • [26] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    LUNG CANCER, 2021, 156 : S40 - S40
  • [27] Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
    Giuseppina Improta
    Angela Zupa
    Maria Iole Natalicchio
    Lorenza Sisinni
    Anna Marinaccio
    Giovanni Bozza
    Giulia Vita
    Michele Aieta
    Matteo Landriscina
    Medical Oncology, 2018, 35
  • [28] Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
    Improta, Giuseppina
    Zupa, Angela
    Natalicchio, Maria Iole
    Sisinni, Lorenza
    Marinaccio, Anna
    Bozza, Giovanni
    Vita, Giulia
    Aieta, Michele
    Landriscina, Matteo
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [29] TYROSINE KINASE INHIBITORS VERSUS CHEMOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATION: VENEZUELAN EXPERIENCE
    Oblitas, George A.
    Bustamante Alvarez, Jean G.
    Fuentes, Maria B.
    Rodriguez, Juan J.
    Garcia, Cristina
    Perez, Maria A.
    Kubicec, Karen
    Nunes, Patricia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S595 - S595
  • [30] Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience
    Bonomi, M.
    Bonomi, L.
    Sauta, M. G.
    Bettini, A. C.
    Squadroni, M.
    Brena, F.
    Cerchiaro, E.
    Ripa, C.
    Salvini, P.
    Beretta, G. D.
    Tondini, C.
    Ceresoli, G. L.
    ANNALS OF ONCOLOGY, 2016, 27
12345